For a company whose valuation rests largely on a single regulatory event, Aquestive Therapeutics heads into its third-quarter report with an unusually clear test. In August, management said the Anafilm new drug application would be resubmitted to the FDA during the third quarter. That would be less than eight months after the January complete response letter. The quarter is now over, and the November 3 release, due after the close, should show whether that promise was kept and whether the review clock is running.
The financial bar is modest. Analysts expect a loss of $0.10 per share, better than the $0.14 loss a year ago. Revenue is expected at $11.0 million, a 13.9% decline from the year-ago quarter and a step down from the $13.8 million posted in the second quarter. That cooling is consistent with management's own outlook. The company reaffirmed 2026 revenue guidance of $46 million to $50 million rather than raising it, even after first-half sales of $28.3 million. That range implies only about $17.7 million to $21.7 million in the second half, or roughly $9 million to $11 million per quarter. The $11.0 million quarterly consensus therefore sits at the top end of what guidance implies. The full-year Street estimate of about $52 million sits above the range entirely. A print near $11 million would validate the base business. Anything closer to $9 million would still be inside guidance but could pressure the stale full-year numbers.
The base business deserves more scrutiny than usual. Second-quarter growth came from Suboxone and a new Zevra royalty, which lifted license and royalty revenue to $1.3 million. Investors should look for evidence that the royalty stream is holding and that Suboxone volumes have not softened. They should also listen for any spillover from the Indivior-Supernus combination or Cosette's Sympazan deal. Management saw no near-term impact from either, but that assurance needs repeating with a quarter of evidence behind it. On costs, second-quarter SG&A was inflated by roughly $2.1 million in legal expenses and $1.4 million in severance. A cleaner expense line would support the narrowing-loss story. The reaffirmed adjusted EBITDA loss range of $30 million to $35 million is well above the second quarter's $5.2 million run rate, which suggests heavier spending ahead, presumably for launch readiness. How fast that ramp begins matters.
The bigger items are regulatory and strategic. The human factors and pharmacokinetic studies came back clean last quarter. Opening difficulties fell to one case from 26, and film tears fell to zero. Confirmation of a completed resubmission, any word on whether the FDA granted expedited review, and an expected action date would turn those results into a timeline. Management also targeted ex-US filings in Canada, Europe and the U.K. to begin in the fourth quarter. Pricing and payer strategy were deliberately kept confidential, and any added color would be welcome. With $98.5 million in cash and $95 million in approval-contingent funding from RTW and Oaktree, financing is less of a near-term worry than it was before the refinancing.
The market has not given management credit for that improving tone. Shares are down 7% since the August report, trailing the S&P 500 by nearly six points. At $3.97, the stock sits below its 200-day moving average of $4.21 and closer to the $3.65 post-earnings low than the $5.49 high. Sentiment has also soured noticeably, moving from barely bearish going into last quarter to clearly bearish now. That skepticism lowers the bar somewhat but also signals doubt about timing.
Ultimately, this report will be judged less on the revenue line than on the regulatory calendar. If Aquestive confirms Anafilm is back in front of the FDA with a defined review path, and the base business lands near the top of its implied guidance, last quarter's de-risking narrative remains intact. Any slip in the resubmission timing would undercut the central reason to own the stock.